Catch up with our insights on the big issues in pharma.
Our thought leadership library brings you our latest data-driven reports, infographics and articles that tackle the big issues, interesting niches and everything in between.
Biopharma entered 2026 with cautious optimism. Where do we stand at the end of the first quarter?
M&A accelerated sharply in March. IPO activity gathered pace before pausing again. Venture capital held steady,...
Loss of exclusivity is accelerating disruption across pharma, putting billions in revenue at risk and testing the limits of traditional forecasting.
As patent cliffs approach, forecasting teams must model not just dec...
Global biopharma alliances reached $269.5B across 642 deals, with average disclosed values up 37% year over year. M&A activity generated $201.2B, driven by multiple multi‑billion‑dollar acquisitions,...
Biopharma deal-making rebounded strongly in 2025, with rising confidence, larger transactions, and record alliance values shaping the year. Our latest Deal-making Roundup brings together the key numbers,...
Biopharma capital returned in 2025. But not for everyone.
After a significant dry spell, capital began to flow back into biopharma in 2025. Though not everyone benefited.
Deals were fewer but larger. Venture...
Orphan drug developers are navigating a more complex landscape.
FDA decision making has proved unpredictable, and rare disease programs must compete for attention as investment flows toward obesity and...
